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 OBJECTIVES:  Treatment for celiac disease (CD) is a lifelong strict gluten-free diet (GFD). Patients should be 
followed-up with dietary interviews and serology as CD markers to ensure adherence to the diet. 
However, none of these methods offer an accurate measure of dietary compliance. Our aim was 
to evaluate the measurement of gluten immunogenic peptides (GIP) in stools as a marker of GFD 
adherence in CD patients and compare it with traditional methods of GFD monitoring.
 METHODS:  We performed a prospective, nonrandomized, multicenter study including 188 CD patients on GFD 
and 84 healthy controls. Subjects were given a dietary questionnaire and fecal GIP quantiﬁ ed by 
enzyme-linked immunosorbent assay (ELISA). Serological anti-tissue transglutaminase (anti-tTG) IgA 
and anti-deamidated gliadin peptide (anti-DGP) IgA antibodies were measured simultaneously.
 RESULTS:  Of the 188 celiac patients, 56 (29.8%) had detectable GIP levels in stools. There was signiﬁ cant 
association between age and GIP in stools that revealed increasing dietary transgressions with 
advancing age (39.2% in subjects ≥13 years old) and with gender in certain age groups (60% in 
men ≥13 years old). No association was found between fecal GIP and dietary questionnaire or anti-
tTG antibodies. However, association was detected between GIP and anti-DGP antibodies, although 
46 of the 53 GIP stool-positive patients were negative for anti-DGP.
 CONCLUSIONS:  Detection of gluten peptides in stools reveals limitations of traditional methods for monitoring GFD in 
celiac patients. The GIP ELISA enables direct and quantitative assessment of gluten exposure early 
after ingestion and could aid in the diagnosis and clinical management of nonresponsive CD and 
refractory CD. Trial registration number NCT02711397.
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 INTRODUCTION
 Celiac disease (CD) is an immune-mediated systemic disor-
der elicited by the ingestion of gluten in genetically susceptible 
individuals. It has a prevalence of 1–3% in the general Western 
population, including the United States ( 1 ), and it is character-
ized by the presence of a varied array of gluten-dependent clinical 
manifestations, CD-specifi c antibodies, HLA-DQ2 or HLA-DQ8 
haplotypes, and enteropathy ( 2–4 ).
 Th e treatment of CD is a lifelong strict gluten-free diet (GFD). 
Th e goal of this treatment is to relieve symptoms, achieve mucosal 
healing, and avoid the complications associated with untreated 
CD ( 5 ). However, although adhering to a GFD might seem simple, 
completely avoiding gluten in the gluten-rich Western diet is chal-
lenging and can considerably aff ect the patient’s quality of life ( 4 ). 
Estimated compliance rates vary considerably (17–80%), depend-
ing on the patient’s age or the age at diagnosis, among other factors 
( 6–10 ).
 Th e adherence to the GFD can be assessed through a dietary 
interview performed by a registered dietitian, or patient self-
reports, and by a small bowel biopsy follow-up showing mucosal 
healing or CD serological screening tests showing decreasing 
levels of antibodies. However, none of these methods off er an 
accurate measure of dietary compliance. Patient self-reports are 
considered unreliable because individuals tend to inaccurately 
report their level of adherence, whether intentionally or unin-
tentionally. Although the normalization of the small intestinal 
architecture on multiple biopsies is a defi nitive evidence of a cor-
rect dietary treatment CD, there is no consensus on the relevance 
of the follow-up biopsies, especially in asymptomatic patients in 
whom clinical improvement is seen ( 8,11 ). Many physicians there-
fore rely on follow-up serologies to monitor compliance with the 
diet. Unfortunately, data clearly show that serology at follow-up 
has a poor correlation with mucosal healing and therefore 
relying solely on serology may underestimate the activity of CD 
( 12–16 ).
 We recently described a novel method to monitor the adherence 
to the GFD by detection of immunodominant gluten peptides 
in human feces using the anti-α -gliadin G12 antibody ( 17–19 ). 
Gluten peptides, in particular peptides related to the immunotoxic-
α −gliadin-33-mer peptide, are resistant to gastrointestinal diges-
tion that ensures that a signifi cant amount of the ingested gluten is 
excreted in feces. Consequently, recovery of detectable amounts of 
the immunotoxic fraction in feces indicates that gluten has passed 
through the digestive tract and, therefore, that gluten has been 
consumed ( 19 ).
 Our aim in this study has been to display the clinical useful-
ness of this new method of measuring fecal gluten immunogenic 
peptides (GIP) as a marker of adherence to GFD. We prospec-
tively examined the compliance to the GFD of both celiac chil-
dren and adults in a multicenter clinical trial. Furthermore, the 
response rate to GFD was evaluated by dietary questionnaire, 
celiac serology, and clinical response. Correlations between 
fecal GIP and traditional methods to monitoring the GFD were 
investigated.
 METHODS
 Study design and participants
 Th is was a prospective, nonrandomized, partially blinded, mul-
ticenter study including CD patients on a GFD and healthy con-
trols recruited between April 2012 and June 2014 at 13 Spanish 
hospitals. Th e study was approved by the ethics committee of each 
institution involved and written informed consent was obtained 
from all participants ≥12 years old, or from the parents or legal 
guardians in the case of children <12 years old.
 Th e study group consisted of celiac patients following a GFD 
for at least 1 year before the inclusion in the study and they were 
required to have an HLA-DQ2 or HLA-DQ8 haplotype and an 
histologically abnormal duodenal biopsy (grade Marsh IIIB or 
IIIC) at the time of diagnosis, supported by positive serum anti-
endomysium IgA antibodies and/or anti-tissue transglutaminase 
(anti-tTG) IgA antibodies. Th e control group comprised healthy 
asymptomatic subjects in whom CD had been ruled out and who 
were not suspected of having any other gastrointestinal condition.
 Exclusion criteria for all study patients included history of 
kidney or liver disease, and history of severe psychiatric disease or 
seizure disorder. Patients in the study group who were unable to 
give informed consent or who were voluntarily following a GFD 
or a diet containing low gluten without medical prescription in the 
months before the inclusion in the study were also excluded.
 All subjects meeting the inclusion criteria for the study were 
given a dietary questionnaire to complete at home and then invited 
for a follow-up visit in which stool and blood samples were col-
lected. Family history of CD and data on the date of CD diagnosis, 
duration of the GFD, and clinical outcome were also collected for 
the study group.
 All authors had access to the study data, and reviewed and 
approved the fi nal manuscript.
 Feces and blood collection
 Subjects were instructed to collect 2–4 g of stool sample in a sealed 
container aft er recording their food intake for 4 days. Specimens 
were dropped off  within 24 h of collection and were kept at −20 °C 
at all times until processing.
 Blood samples were collected in two 3 ml vacutainer tubes 
with EDTA-K3 anticoagulant and centrifuged at 2,000  g within 
30 min of collection to obtain plasma. Processed sera were stored 
at −80 °C until analysis. All samples were identifi ed and labeled 
with a randomized numeric-code.
 Quantiﬁ cation of GIP in stool samples
 Th e concentration of GIP in stools was measured by sandwich 
enzyme-linked immunosorbent assay (ELISA) using the iVYDAL 
 In Vitro Diagnostics iVYLISA GIP-S kit (Biomedal S.L., Seville, 
Spain) following the manufacturer’s guidelines. Briefl y, stool sam-
ples were incubated for 60 min at 50 °C with gentle agitation in 
9 ml of Universal Gluten Extraction Solution (UGES; Biomedal 
S.L.) per g of stool to release the GIP from the stool matrix. Aft er 
extraction, samples were diluted 1:10 and incubated for 60 min 
in the provided microtiter plate coated with G12 together with 
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the standards and the assay’s positive and negative controls. 
Wells were then washed and samples incubated with horseradish 
peroxidase-conjugated G12 antibody for another 60 min. Subse-
quently, plates were washed again and incubated with the horse-
radish peroxidase substrate. Color development was stopped with 
sulfuric acid and absorbance measured at 450 nm using micro-
plate reader UVM340 (Asys Hitech GmbH, Eugendorf, Austria). 
Th e results were expressed as μ g GIP per g feces. Each sample was 
run in duplicate and at least two diff erent aliquots of each sample 
were tested on diff erent days.
 Validation of the detection method and determination of cutoff 
values
 Validation of the G12 sandwich ELISA was performed by deter-
mining the analytical sensitivity and the diagnostic sensitivity and 
specifi city. Th e analytical specifi city, defi ned as the ability of the 
method to exclusively detect the analyte ( 20 ) (in this case GIP), 
was not evaluated in this study because it has previously been 
estimated using samples from cereals and other food samples 
( 17,18,21–24 ).
 Assessment of the analytical sensitivity was performed by deter-
mining the limit of detection, which is the lowest detectable con-
centration of an analyte, and the limit of quantifi cation (LOQ), 
which is the lowest quantifi able concentration of the analyte. Th e 
limit of detection was calculated by running 10 replicates of one 
negative sample and set at the mean+3×s.d. and the LOQ was 
calculated experimentally using spiked samples ranging between 
0.078 and 100 μ g GIP per g sample. For diagnostic purposes, all 
samples with values below the LOQ were considered negative and 
all those above the LOQ were considered positive.
 For calculating the diagnostic sensitivity, defi ned as the propor-
tion of subjects who are positive for the condition of study and 
who are identifi ed as positive by the diagnostic method ( 25 ), the 
samples from 73 healthy subjects known to be on a gluten-contain-
ing diet (positive controls) were used. Th e percentage of those with 
positive GIP values in stools was calculated.
 Similarly, the diagnostic specifi city, defi ned as the proportion of 
subjects negative for the study condition and who are identifi ed 
as negative by the diagnostic method ( 25 ), was calculated using 
stool samples obtained from 11 healthy infants who had never 
ingested gluten. Of the 11 patients, 9 were younger than 6 months 
and were fed only GF formula and the other 2 patients were 7 and 
8 months old, and consumed, besides infant formula milk, age-
related complement of fruit, vegetables, rice, and maize, but in 
no case did their diet include any product suspected to contain 
gluten. Breastfed babies were excluded to avoid the possibility of 
gluten ingested by the mother being excreted into the breast milk 
and transferred to the baby. Th e percentage of babies with negative 
GIP values was then calculated to obtain the specifi city of the G12 
sandwich ELISA.
 Determination of anti-tTG and anti-gliadin antibodies
 Th e levels of anti-tTG IgA and anti-deamidated gliadin peptide 
(anti-DGP) IgA antibodies (or anti-DGP IgG in total IgA-defi -
cient patients) were determined by ELISA using the EliA Celikey 
IgA and EliA Gliadin IgA/IgG kits, respectively, according to the 
manufacturer’s protocol (Phadia, Freiburg, Germany). Measure-
ments were performed in duplicates and the results expressed as 
EliA U/ml. Sera were considered positive when >10 U/ml as indi-
cated in the manufacturer’s specifi cations.
 Dietary questionnaire
 To assess gluten exposure, a structured food questionnaire of 27 
items was administered to both study patients and controls to 
record the foods consumed during the 4 days before the collection 
of the stool and blood specimens. Th e food items were classifi ed 
into eight predefi ned groups: dairy (milk and cheese); complex 
carbohydrates (bread, cereals, pasta, rice, potato, legumes, and 
nuts); meats (red meat, fi sh, cold cuts, and eggs); fruits (whole 
or juiced); vegetables; fats (vegetable oils, butter, and cream); 
sweetened beverages (sodas, bottled juices, and energy drinks); 
and other (baked goods, candy, snacks, etc.). Images of standard 
portion sizes were included as a guideline for portion quantifi ca-
tion. Subjects were asked to record the amount and type of food 
consumed, brand, time of meal, and if it was labeled as gluten-
free. Th ey were also asked to note if they were aware of having 
consumed any gluten-containing foods.
 Statistical analysis
 Data analysis was performed with SPSS 23.0 for Windows (SPSS, 
Armonk, NY). Values obtained by ELISA for each sample were 
expressed as mean±s.d. Frequency distributions were calculated 
for all groups and expressed as relative percentages.
 Th e χ 2 or Fisher’s exact test were used to assess the strength of 
association between categorical variables and Kruskal–Wallis or 
Mann–Whitney nonparametric tests were used to compare diff er-
ences between groups. A statistical probability of  P <0.05 was con-
sidered signifi cant for all analyses.
 RESULTS
 Characteristic of the participants
 A total of 340 subjects were recruited and 272 (153 females and 
119 males) were included in the fi nal study aft er excluding 68 
patients who dropped out. Th e demographic characteristics of the 
individuals enrolled in the study are outlined in  Table 1 .
 Th ere were 188 GFD-treated celiac patients (age range 1–72 
years) and 84 healthy controls (age range 0–66 years) who met 
inclusion criteria for the study. Th e control group comprised: 
(i) positive controls ( n =73), healthy children and adults on an 
unrestricted gluten-containing diet; and (ii) negative controls 
( n =11), healthy infants between 0 and 8 months of age who did 
not include in their diet any product suspected to contain gluten; 
breastfed babies were excluded to avoid the possibility of gluten 
ingested by the mother being excreted into the breast milk and 
transferred to the baby.
 Sensitivity and speciﬁ city of the analytical method
 To assess the validity of the G12 sandwich ELISA method in 
detecting GFD transgressions, both the analytical sensitivity and 
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the diagnostic sensitivity and specifi city of the test were deter-
mined.
 Th e limit of detection and LOQ that defi ne the analytical sen-
sitivity were found to be 0.06 (mean of 10 negative sample repli-
cates+3 s.d.) and 0.156 μ g GIP per g feces, respectively. Of the 73 
healthy subjects known to be on a gluten-containing diet (positive 
controls), 72 had GIP levels above the LOQ and as such were cor-
rectly identifi ed as being positive by the immunoassay, whereas all 
the healthy infants on a GFD formula (negative controls) had GIP 
levels below the LOQ and thus were correctly considered negative, 
yielding a diagnostic sensitivity and specifi city of 98.5% and 100%, 
respectively. Th e results obtained were classifi ed into three ranges 
depending on the GIP concentration and repeatability of value in 
diff erent aliquots of the same sample: (i) negative values in GIP 
were below the LOQ; (ii) weak positive values were close to the 
LOQ (between 0.16 and 0.30 μ g GIP per g feces), and in repeated 
analysis of diff erent aliquots of the same stool, one of them could 
yield negative results and; (iii) strong positive values with >0.30 μ g 
GIP per g feces always were positive in all the tested aliquots of the 
same sample.
 Evaluation of GFD adherence by fecal GIP content in celiac 
patients
 Stool samples from celiac patients on a GFD and healthy controls 
were tested for the presence of GIP by ELISA using the iVYLISA 
GIP-S kit. Of the 188 celiac patients examined, 56 (29.8%) were 
found to have detectable amounts of GIP in stools. On the con-
trary, all 73 positive controls on a gluten-containing diet except 1 
(98.5%) had quantifi able amounts of GIP in stools (94.1% strong 
positive, 4.4% weak positive). Th e mean GIP concentrations 
obtained with this method were higher in the positive controls 
than in the celiac patients who had all been following a GFD for 
>1 year ( P <0.001,  Figure 1 ). As expected, none of the negative 
controls had measurable levels of GIP ( Figure 1c ).
 In order to assess whether age, sex, duration of GFD, or fam-
ily history of CD had an eff ect on GFD compliance, we analyzed 
the association of each of these parameters with the presence of 
GIP in stools. To evaluate the eff ect of age, we categorized the 
celiac patients according to their ability to make independent 
food choices into the three following groups: (i) 0–3 year olds 
( n =35), children who presumably have little to no ability to 
control what they eat; (ii) 4–12 year olds ( n =79), children with 
moderate autonomy and thus with risk of making dietary trans-
gressions eating at home or when dining out; (iii) ≥13 year olds 
( n =74), teenagers and adults with a high degree of autonomy to 
make food choices. We found a positive signifi cant association 
between age and GIP content in stools that revealed increasing 
dietary transgressions with advancing age ( P =0.025,  Figure 2a ). 
Th e majority (85.7%) of celiac children between 0 and 3 years of 
age had stool samples negative for GIP, with only 14.3% show-
ing levels above the LOQ (5.7% strong positive and 8.6% weak 
positive). Th e proportion of celiac patients with stool samples 
positive for GIP increased to 27.8% in children between 4 and 12 
years of age, half of whom were weak positive. Among those ≥13 
years old, the proportion rose up to 39.2% with strong and weak 
positive. Although GIP-positive stools were more common in 
the older children and adults, no signifi cant diff erence was seen 
in GIP concentrations across the diff erent age groups ( P =0.337, 
 Figure 2b ).
 When further stratifi ed by gender, adherence to the GFD was 
found to be closely related to the patient’s gender in certain age 
groups. Although the percentage of celiac patients positive for 
fecal GIP increased with age in both men and women, there was 
no signifi cant diff erence between males and females <13 years 
old ( P =0.782 for 0–3-year age group and  P =0.834 for 4–12-year 
age group). In contrast, more men in the ≥13-year-old group had 
positive GIP stools compared with women in the same age group 
 Table 1 .  Characteristics of patients enrolled in the study 
 Characteristics  Patients,  n  (%) 
 Total  272  
 Sex 
 Male  119  43.8 
 Female  153  56.2 
 Mean age at recruitment (21.7)   
 Patients enrolled 
 Healthy controls  84  30.9 
 Celiac patients  188  69.1 
 Celiac patients 
 Total  188  
  Mean age at recruitment 
   0–3 Years  35  18.6 
   4–12 Years  79  42.0 
   ≥13 Years  74  39.4 
  Time on GFD 
   1–<2 Years  96  51.1 
   2–5 Years  54  28.7 
   ≥6 Years  38  20.2 
 Healthy controls 
 Total  84  
 Positive controls 
 Total  73  
  Mean age at recruitment 
   0–3 Years  6  8.2 
   4–12 Years  6  8.2 
   ≥13 Years  61  83.6 
 Negative controls 
  Total  11  
  Mean age at recruitment 
  0–8 Months  11  100.0 
 GFD, gluten-free diet. 
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 Th e association between the percentage of GIP-positive stools in 
celiac patients and the duration of the GFD is shown in  Figure 3 . 
Although no overall signifi cant diff erences were observed, the 
patients who had been on the GFD for a longer period of time 
showed higher rates of noncompliance as evidenced by the higher 
(60% vs. 31.5%,  P =0.034), indicating higher number of dietary 
transgressions among men than in their female peers. In this oldest 
age group, 30.0% of men as opposed to 13.0% of women had 
strong positive GIP values in stools, and 30% vs. 18.5% had weak 
positive levels.
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percentages of GIP-positive stools. Patients on the diet ≥6 years 
were more likely to have GIP-positive stools than patients on the 
diet for 2–5 years or only 1 year (36.8%, 33.3%, and 25%, respec-
tively). No signifi cant association was found between GIP levels in 
celiac patients and history of CD in their fi rst- or second-degree 
relatives (data not shown).
 Assessment of GFD adherence by dietary questionnaire and 
association with fecal GIP
 Celiac patients and positive controls were asked to fi ll out a struc-
tured dietary questionnaire to assess their GFD compliance during 
the 4 days before the collection of the stool and plasma samples. 
Questionnaires were considered complete if they included infor-
mation on type of food, brand, and portion size for at least 80% 
of the food items consumed on the fi rst 3 days of the study. Food 
data from day 4 of the query was excluded, as foods consumed on 
the day before the sample collection would have had insuffi  cient 
time to pass through the digestive tract given an ≈4-h gastric/
small bowel ( 26 ) plus 7.2–86.4-h colonic transit time ( 19,27 ).
 Of the 188 celiac patients who fi lled out dietary questionnaires, 
50 (26.6%) were incomplete and thus were excluded from data 
analysis. For the remaining 138 patients, questionnaires were 
assessed for the consumption of gluten-containing foods with 
special emphasis on food products containing wheat, rye, barley, 
and oats. As shown in  Table 2 , among the 138 celiac patients who 
were assessed for GFD compliance by both fecal GIP and food 
questionnaire, 39 (28.3%) were considered noncompliant by fecal 
GIP analysis, whereas only 25 (18.1%) were noncompliant accord-
ing to the food questionnaire, with only 9 (6.5%) of the total celiac 
patients being noncompliant by both methods. Of the 99 patients 
deemed to be gluten free by fecal GIP analysis, 82 (82.8%) were also 
believed to be compliant by questionnaire analysis. Conversely, of 
the 39 celiac patients considered to have consumed gluten by fecal 
GIP analysis, 27 (69.2%) did not declare any gluten consumption 
in the questionnaire. Analysis by Fisher’s exact test failed to detect 
any association between the two methods but approached signifi -
cance ( P =0.055).
 Correlations between fecal GIP and serum antibodies
 As shown in  Figure 4 , positivity for both anti-tTG IgA and GIP 
in stools was found in 14 patients. However, anti-tTG IgA was 
negative in 40 of the 56 patients with GIP-positive stools. Th ere-
fore, there was no signifi cant association between fecal GIP 
and anti-tTG IgA ( P =0.230). In contrast, we found an associa-
tion between GIP and anti-DGP IgA levels ( P =0.044). Elevated 
anti-DGP IgA titers were found in 11 patients, 6 of whom were 
also positive for GIP in stool. Negative anti-DGP IgA levels were 
found in 160, and of these, 114 had undetectable levels of GIP in 
stools as well.
 Association between fecal GIP content and clinical outcome
 Clinical data were available for 182 of the 188 participating celiac 
patients. From them, only 9 (4.9%) reported persistent symptoms 
despite being on a GFD for ≥12 months (median 2.6 years range 
1–5). Of these, 7 were males and 2 females with a total median 
age of 22.4 years (range 8–46). Th e most frequent symptoms or 
analytical abnormalities were iron defi ciency anemia ( n =4), diar-
rhea ( n =3), abdominal pain ( n =3), weight loss ( n =1), dermatitis 
herpetiformis ( n =1), short stature ( n =1), and constipation ( n =1). 
All 9 symptomatic patients had negative celiac serological mark-
ers at the time of stool sample collection except 2 (22.2%) who 
were positive for anti-tTG IgA and another two who were for anti-
DGP IgA antibodies; no patients were positive for both anti-tTG 
and anti-DGP.
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 Figure 3 .  Percentage distribution of celiac patients according to GIP 
content in stools and duration of GFD. GFD, gluten-free diet; GIP, gluten 
immunogenic peptides. 
 Table 2 .  Evaluation of GFD adherence by fecal GIP and dietary questionnaire 
  GIP positive  GIP negative  Total 
 Dietary questionnaire  n  %  n  %  n  % 
  39   99   138  
 GFD noncompliant  9  23.1  16  16.2  25  18.1 
 GFD compliant  27  69.2  82  82.8  109  79.0 
 Inconclusive a  3  7.7  1  1.0  4  2.9 
 GFD, gluten-free diet; GIP, gluten immunogenic peptides. 
 a Inconclusive, dietary questionnaire containing foods that could not be objectively assessed for gluten content. 
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current study, using a direct and quantitative method of gluten 
detection in feces we found that the number of celiac patients non-
compliant with the diet ranged from 15% in children ≤3 years old 
to almost 40% in teenagers and adults. Th is association between 
lack of GFD compliance and advancing age is likely due to the 
patient’s increasing autonomy and ability to make dietary choices 
that would increase the risk of dietary transgressions. Children ≤3 
years old, on the other hand, are highly dependent on their parents 
to be fed and would have strict control over the diet. Moreover, we 
found that among subjects ≥13 years old, dietary transgressions 
were signifi cantly more frequent in men than in their female peers, 
as indicated by the positive levels of GIP found in the stools of up 
to 60% of men compared with ~30% of women within the same 
age group. Th e higher proportion of noncompliant male patients 
compared with females could be attributed to milder symptoms 
found in men or to stricter self-control over the diet in women. 
In addition, we also observed a tendency for more patients to be 
noncompliant the longer they had been on the diet. Altogether, 
these data show how increasing control over the diet could yield 
an increase in dietary adherence, as demonstrated by the fourfold 
greater adherence seen in children ≤3 years old who have strong 
parental control over their diet but no social pressure as compared 
with the adherence of 13 year olds and older adult males who 
are under little parental control but are subject to strong social 
infl uences.
 Th ere is considerable controversy over whether the evaluation of 
adherence to a GFD during clinical follow-up should be based on 
dietary questionnaires, symptom improvement, reduction of CD-
related antibodies, histological recovery, or a combination of these 
parameters. Small bowel biopsy for the assessment of mucosal 
infl ammation and villous atrophy is the “gold standard” for CD 
diagnosis. Th erefore, mucosal healing would be the ideal parame-
ter to monitor GFD adherence and for clinical management. How-
ever, because of its invasiveness, relative risk, and cost (especially 
 Analysis of the association between presence of GIP in stools 
and clinical outcome revealed a signifi cant association between 
GIP and symptoms typical of gluten consumption ( P =0.019). Of 
the 9 patients with persistent symptoms, 3 (one-third) had unde-
tectable levels of GIP in stools by GIP ELISA but 6 were positive, 
indicating that gluten exposure could be responsible for the symp-
toms in two-thirds of the celiac patients not responding to the 
diet. In addition, 27.2% (47 out of 173) of the asymptomatic celiac 
patients had detectable levels of GIP in stools, 44.6% of them (21 
cases) being strong positive. Interestingly, 5 (out of 6) of the symp-
tomatic and 20 (out of 47) of the asymptomatic GIP stool-positive 
patients reported gluten consumption in the food questionnaire.
 DISCUSSION
 Th is is the fi rst multicenter study to assess dietary compliance to 
a GFD in celiac patients based on the quantifi cation of GIP in 
stools. GIPs are excreted in feces only when gluten is ingested, 
thus detection in stools of celiac patients on a GFD implies that 
there has been gluten exposure and that a dietary transgression 
has been made. Our results showed that ∼ 30% of the analyzed 
celiac patients on a GFD for at least a year had detectable amounts 
of GIP in their stools, suggesting that almost one-third of the 
celiac patients on a GFD were not compliant. In contrast, non-
compliance was detected in ∼ 18% of the patients when assessing 
adherence either by dietary questionnaire or by determination of 
anti-tTG antibodies in serum alone.
 Prior studies using indirect methods based on dietary self-
reports, food interviews, or follow-up serologies have estimated 
that between 17 and 80% of celiac patients are not compliant with 
the GFD ( 6–10 ). Th e variation found in the rate of adherence 
between the diff erent studies may be due to diff erences in study 
design, the method used for evaluation of compliance, and/or 
diff erences in the characteristics of the study population. In the 
100
80
60
40
20Pe
rc
en
ta
ge
 o
f t
ot
al
fre
qu
en
cy
 o
f a
nt
i-t
TG
0 GIP strong
positive
Anti-tTG n
26 30
6
1
23
20.0
127 183
32 17.5
4.4
78.1
8
143
14.2
4.7
81.1
18
6
103
3.3
76.7
30.8
3.8
65.4
8
1
17
% n % n % n %
Total
Positive
Doubtful
Negative
GIP weak
positive GIP negative Patients total
100
80
60
40
20Pe
rc
en
ta
ge
 o
f t
ot
al
fre
qu
en
cy
 o
f a
nt
i-D
G
P
0 GIP strong
positive
Anti-DGP n
24 29 119 172
11 6.4
0.6
93.0
1
160
4.2
0.0
95.8
5
0
114
2 6.9
3.4
89.7
1
26
16.7
0.0
83.3
4
0
20
% n % n % n %
Total
Positive
Doubtful
Negative
GIP weak
positive GIP negative Patients total
a b
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in asymptomatic patients), small bowel biopsy is not a practical 
method for monitoring disease activity and assessing dietary com-
pliance in celiac patients ( 6 ).
 Dietary questionnaires, although considered to be helpful in 
evaluating diet compliance ( 16 ), are subjective and rely on the 
patient’s knowledge of the GFD and honesty when completing the 
questionnaire to accurately determine compliance ( 28,29 ). In this 
study, although ∼ 18% (25 out of 138) of the celiac patients studied 
were considered not compliant according to the food question-
naire, only 9 out of 25 patients had also detectable levels of GIP 
in stools. Interestingly, 70% of the patients who showed positive 
levels of GIP in stools did not declare any gluten consumption in 
the food questionnaire. Th is could be because of the patients pur-
posely not recording the gluten consumption in the questionnaire 
or inadvertent gluten ingestion that the questionnaire, as opposed 
to the GIP ELISA, would not be able to detect.
 Some clinical researchers, in the absence of other practical 
alternatives, have recommended that serology should be per-
formed annually to monitor adherence ( 8,30 ). However, recent 
studies have shown serology should not be considered a surrogate 
marker of intestinal recovery and ought to be used as a measure of 
mucosal healing only if supported by a small bowel biopsy showing 
improvement of the intestinal damage ( 15,30–33 ). In the present 
work, patients with strong positive values for GIP in stools were 
2 and 4 times more likely to have positive anti-tTG and anti-DGP 
IgA antibodies, respectively, than patients with undetectable levels 
of GIP. However, of the patients with GIP levels >30 μ g per g of 
feces, 65% had negative anti-tTG-IgA antibody titers and 83% had 
negative anti-DGP-IgA antibodies that would be consistent with 
prior reports on the low sensitivity of the serology for monitoring 
response to the diet.
 Although seemingly intuitive, clinical response is not an opti-
mal method for monitoring adherence to the GFD as a large 
number of celiac patients are asymptomatic or minimally symp-
tomatic at presentation and in these cases it would not be feasi-
ble to use clinical response as an indicator of mucosal healing and 
GFD compliance ( 31 ). A controlled study examining the eff ects 
of gluten challenge found that symptoms were absent in 22% of 
celiac patients despite the presence of signifi cant villous atrophy in 
the small bowel biopsy ( 34 ). Although the patients who reported 
symptoms despite being on a GFD for at least 12 months were few 
in this study (4.9%), we found a high correlation between the pres-
ence of symptoms and GIP with almost 67% of the symptomatic 
patients having detectable levels of GIP in stools, and this would 
indicate that gluten consumption, whether voluntary or inadvert-
ent, could be responsible for the symptoms in these patients. Th ese 
results are consistent with previous studies showing that even aft er 
adoption of a GFD, 4–30% of patients report persistent symptoms 
( 5 ), and that gluten exposure is the most frequent cause of not 
responding to the diet, with only 10% being considered to have 
refractory CD ( 28 ).
 Refractory CD is characterized by the persistence of symptoms 
and villous atrophy despite adherence to a strict GFD for >12 
months. Th e diagnosis requires exclusion of other diseases that 
can cause similar symptoms and villous atrophy as well as the 
confi rmation of a strict GFD. Detection of GIP in stools using the 
immunoassay described in this study would be a valuable tool in 
the diff erential diagnosis of refractory CD. In this study we found 
that 67% of the celiac patients with persistent symptoms despite 
being on a GFD had detectable levels of GIP in their stools and 
therefore could be having refractory CD if no other causes for the 
persistent symptoms are found. As both the presence of symptoms 
and GIP in stools may indicate potential dietary infringement, 
their joint use could have a high positive predictive value for moni-
toring the dietary compliance of celiac patients.
 Similar fi ndings to the ones observed in this study using GIP 
quantifi cation in stools have recently been published by our 
group measuring GIP in urine with immonochromatographic 
strips ( 35 ). In this prior study we found that GIP is detectable in 
urine 6–48 h aft er gluten ingestion, whereas it has been shown to 
remain detectable in stools for up to 4 days ( 19 ). Urine analysis 
could be used in conjunction with the fecal test for early detection 
of dietary infringements and the monitoring of GFD compliance 
in CD.
 Th e inability to directly measure GFD adherence is an unsolved 
problem for both clinicians and researchers and for which the 
analysis of GIP is a possible solution. Clinically, GIP analysis 
would allow celiac patients to detect unintentional gluten contam-
ination and prevent the complications associated with untreated 
CD. In addition, during a gluten challenge it could be used to 
verify gluten consumption and avoid the underdiagnosis of CD. 
Clinical research for the development of novel therapies in CD 
could also benefi t from fecal GIP analysis to ensure gluten expo-
sure in control subjects of clinical trials and permit evaluation of 
drug effi  cacy.
 In conclusion, we have observed a low GFD compliance rate 
among patients on an established GFD using GIP analysis that is 
lower than that shown with traditional dietary questionnaire or 
serological methods. Th e method of fecal GIP analysis proposed 
in this work is an accurate method that enables a direct and quanti-
tative assessment of gluten exposure early aft er ingestion. Because 
of its high sensitivity and noninvasive nature it could become the 
method of choice for monitoring adherence to the GFD and a way 
for improving the diagnosis and clinical management of nonre-
sponsive CD and refractory CD.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  The treatment of celiac disease (CD) is a lifelong strict 
gluten-free diet. 
 ✓  The goal of gluten-free diet is to relieve symptoms, achieve 
mucosal healing, and avoid the complications associated 
with untreated CD. 
 ✓  The adherence to the gluten-free diet varies considerably 
(17–80%). 
 ✓  The adherence to the gluten-free diet can be assessed by 
indirect methods based on dietary self-reports, food inter-
views, or follow-up serologies. None of these methods offer 
an accurate measure of dietary compliance. 
 WHAT IS NEW HERE 
 ✓  This is the ﬁ rst trial to assess dietary compliance to a 
gluten-free diet in celiac patients based on the quantiﬁ ca-
tion of gluten immunogenic peptides in stools. 
 ✓  Fecal gluten immunogenic peptide analysis is an accurate 
and noninvasive method that enables a direct and quanti-
tative assessment of gluten exposure early after ingestion. 
 ✓  Gluten immunogenic peptide analysis reveals a low diet 
compliance rate among patients on a gluten-free diet and 
limitations of dietary questionnaire or serological methods 
for monitoring diet. 
 ✓  Assessment of gluten in stool is a way for improving the 
diagnosis and clinical management of nonresponsive CD 
and refractory CD. 
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